scholarly journals Validation of the BD FACSPresto system for the measurement of CD4 T-lymphocytes and hemoglobin concentration in HIV-negative and HIV-positive subjects

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Xiaofan Lu ◽  
Hanxiao Sun ◽  
Haicong Li ◽  
Wei Xia ◽  
Hao Wu ◽  
...  

Abstract This study aimed to compare the performance of the BD FACSPresto system with the conventional standard-of-care technologies for the measurement of absolute CD4 count (AbsCD4), CD4 percentage (CD4%) and total hemoglobin concentration (Hb) in capillary and venous blood samples of HIV-negative and HIV-positive subjects. A total of 1304 participants were included in this prospective cohort study. Both venous and capillary blood samples were analyzed using the BD FACSPresto system and the results were compared against the BD FACSCalibur for enumerating AbsCD4 and CD4% and Sysmex XT-4000i hematology analyzer for determining Hb levels. Method comparison studies were performed using Deming regression and Bland–Altman plots. The Deming regression analyses comparing the accuracy of the BD FACSPresto system with the reference standard technologies demonstrated a significant linear correlation between the AbsCD4, CD4%, and Hb values generated by the two platforms. The 95% CI of the slopes for AbsCD4, CD4%, and Hb levels were 0.94–0.99, 0.99–1.01 and 0.86–0.93, respectively (P < 0.001). Bland–Altman plots for AbsCD4, CD4%, and Hb levels demonstrated close agreement between the BD FACSPresto system and the reference standards for all study participants. The performance and accuracy of BD FACSPresto system was comparable to the reference standard technologies. The BD FACSPresto system can be used interchangeably with BD FACSCalibur platform for CD4 and Sysmex XT-4000i hematology analyzer for Hb concentrations in resource-limited settings thus, improving accessibility to point-of-care testing services.

2021 ◽  
pp. 2003999
Author(s):  
Monde Muyoyeta ◽  
Andrew D. Kerkhoff ◽  
Lophina Chilukutu ◽  
Emmanuel Moreau ◽  
Samuel G. Schumacher ◽  
...  

BackgroundA novel, rapid, point-of-care urine-based lipoarabinomannan assay (Fujifilm SILVAMP TB-LAM, “FujiLAM”) has previously demonstrated substantially higher sensitivity for tuberculosis (TB) compared to the commercially-available Determine TB-LAM assay using bio-banked specimens. However, FujiLAM has not been prospectively evaluated using fresh urine specimens. Therefore, we determined the diagnostic accuracy of FujiLAM among HIV-positive and HIV-negative outpatients with presumptive TB in Zambia.MethodsAdult (≥18 years) presumptive TB patients presenting to two outpatient public health facilities in Lusaka, were included. All patients submitted sputa samples for smear-microscopy, Xpert Ultra and Mycobacterial culture and urine samples for the FujiLAM assay. Microbiologically-confirmed TB was defined by the detection of Mycobacterium tuberculosis in sputum using culture; this served as the reference standard to assess the diagnostic accuracy of FujiLAM.Results151 adults with paired sputum microbiologic tests and urine FujiLAM results were included; 45% were HIV-positive. Overall, 34/151 (23%) patients had culture-confirmed pulmonary TB. The overall sensitivity and specificity of FujiLAM was 77% (95% CI: 59–89) and 92% (95% CI: 86–96), respectively. FujiLAM's sensitivity among HIV-positive patients was 75% (95% CI: 43–95) compared to 75% (95% CI: 51–91) among HIV-negative patients. The sensitivity of FujiLAM in patients with smear-positive, confirmed pulmonary TB was 87% (95% CI: 60–98) compared to 68% (95%: 43–87) among patients with smear-negative, confirmed pulmonary TB.ConclusionsFujiLAM demonstrated high sensitivity for the detection of TB among both HIV-positive and HIV-negative adults and also demonstrated good specificity despite the lack of systematic extra-pulmonary sampling to inform a comprehensive microbiological reference standard.


2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 922-922
Author(s):  
Amanda Wendt ◽  
Jillian Waid ◽  
Anna Müller-Hauser ◽  
Nicholas Kyei ◽  
Shafinaz Sobhan ◽  
...  

Abstract Objectives Our objective was to compare hemoglobin concentration and anemia prevalence between (1) analysis methods, i.e., the portable HemoCue 201 + and the Sysmex XP-100 automated hematology analyzer, and (2) blood matrix, i.e., venous and capillary, in women and young children. Methods We collected capillary and venous blood samples from 349 non-pregnant women (NPW), 45 pregnant women (PW), and 167 children aged 6–36 months in rural Sylhet Division, Bangladesh in late 2019. We measured hemoglobin concentration in capillary and venous blood using HemoCue 201 + at the point of blood collection in the villages. In addition, hemoglobin concentration was measured in venous EDTA blood samples in the lab using the XP-100 Sysmex automated hematology analyzer within 6 hours of collection. Hemoglobin values were compared using paired t-tests, while anemia prevalence estimates were compared using McNemar tests. Results Venous hemoglobin concentrations were similar (mean difference: 0.3 g/L) when measured by HemoCue and the hematology analyzer. However, among NPW, there was strong evidence that anemia prevalence was higher when measured by HemoCue compared to the hematology analyzer, with similar trends in PW and children. Mean hemoglobin concentrations in capillary blood were lower overall (mean difference: 5 g/L; P ≤ 0.001) and in all subgroups (NPW, PW, and children) compared to venous blood. Anemia prevalence was higher in each population group using capillary (NPW: 37%; PW: 51%; children: 21%) compared to venous measures (NPW: 23%; PW: 36%; children: 10%). Conclusions Across all groups, capillary measures resulted in significantly lower hemoglobin concentrations and higher anemia prevalence estimates, thus likely overestimating anemia in the population. Venous blood samples measured by the two analytic methods were similar. This may point to a biological difference between capillary and venous blood. Funding Sources Data collection was primarily supported by the German Ministry of Education and Research (BMBF). The first author received support from the Alexander von Humboldt Foundation and a Thrasher Research Fund Early Career Award.


Author(s):  
Gomathi Ramaswamy ◽  
Kashish Vohra ◽  
Kapil Yadav ◽  
Ravneet Kaur ◽  
Tripti Rai ◽  
...  

Abstract Introduction Globally around 47.4% of children and in India, 58% of children aged 6–59 months are anemic. Diagnosis of anemia in children using accurate technologies and providing adequate treatment is essential to reduce the burden of anemia. Point-of-care testing (POCT) devices is a potential option for estimation of hemoglobin in peripheral and field settings were the hematology analyzer and laboratory services are not available. Objectives To access the validity of the POCTs (invasive and non-invasive devices) for estimation of hemoglobin among children aged 6–59 months compared with hematology analyzer. Methods The study participants were enrolled from the pediatric outpatient department in Haryana, India, from November 2019 to January 2020. Hemoglobin levels of the study participants were estimated in Sahli’s hemoglobinometer and invasive digital hemoglobinometers (DHs) using capillary blood samples. Hemoglobin levels in non-invasive DH were assessed from the finger/toe of the children. Hemoglobin levels measured in POCTs were compared against the venous blood hemoglobin estimated in the hematology analyzer. Results A total of 120 children were enrolled. The mean (SD) of hemoglobin (g/dl) estimated in auto-analyzer was 9.4 (1.8), Sahli’s hemoglobinometer was 9.2 (1.9), invasive DH was 9.7 (1.9), and non-invasive DH was 11.9 (1.5). Sahli’s hemoglobinometer (95.5%) and invasive DH (92.2%) had high sensitivity for the diagnosis of anemia compared with non-invasive DH (24.4%). In contrast, non-invasive DH had higher specificity (96.7%) compared with invasive DH (83.3%) and Sahli’s hemoglobinometer (70%). Invasive DH took the least time (2–3 min) for estimation of hemoglobin per participant, followed by Sahli’s (4–5 min) and non-invasive DH (5–7 min). Conclusion All three POCT devices used in this study are reasonable and feasible for estimating hemoglobin in under-5 children. Invasive DHs are potential POCT devices for diagnosis of anemia among under-5 children, while Sahli’s can be considered as a possible option, where trained and skilled technicians are available. Further research and development are required in non-invasive DH to improve accuracy. Lay summary In India, anemia is a serious public health problem, where 58% of the children aged 6–59 months are anemic. Point-of-care testing (POCT) using digital hemoglobinometers (DHs) has been recommended as one of the key interventions by the Anemia Mukt Bharat program since 2018 in India. These POCT devices are easy to use, less invasive, can be carried to field, require minimal training and results are available immediately. Therefore this study assessed the validity of POCT devices—invasive DH, non-invasive DH and Sahli’s hemoglobinometer among 6–59 months children in facility setting compared with the gold standard hematology analyzer. A total of 120 children under 6–59 months of age were enrolled from the pediatric outpatient department in Haryana, India, from November 2019 to January 2020. The (mean hemoglobin in g/dl) invasive (9.7) and non-invasive DH (11.9) overestimated hemoglobin value, while Sahli’s (9.2) underestimated hemoglobin compared with hematology analyzer (9.4). Invasive DH (92.2%) and Sahli’s hemoglobinometer (95.5%) reported high ability to correctly identify those with anemia compared with non-invasive DH (24.4%). In contrast, non-invasive DH (96.73%) had higher ability to correctly identify those without the anemia compared with invasive DH (83.3%) and Sahli’s (70%).


PLoS ONE ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. e0256423
Author(s):  
William M. Dickerson ◽  
Rebecca Yu ◽  
Helena U. Westergren ◽  
Jonathan Paraskos ◽  
Philipp Schatz ◽  
...  

Background Point-of-care (PoC) testing of platelet count (PLT) provides real-time data for rapid decision making. The goal of this study is to evaluate the accuracy and precision of platelet counting using a new microvolume (8 μL), absolute counting, 1.5 kg cytometry-based blood analyzer, the rHEALTH ONE (rHEALTH) in comparison with the International Society of Laboratory Hematology (ISLH) platelet method, which uses a cytometer and an impedance analyzer. Methods Inclusion eligibility were healthy adults (M/F) ages 18–80 for donation of fingerprick and venous blood samples. Samples were from a random N = 31 volunteers from a single U.S. site. Samples were serially diluted to test thrombocytopenic ranges. Interfering substances and conditions were tested, including RBC fragments, platelet fragments, cholesterol, triglycerides, lipids, anti-platelet antibodies, and temperature. Results The concordance between the rHEALTH and ISLH methods had a slope = 1.030 and R2 = 0.9684. The rHEALTH method showed a correlation between capillary and venous blood samples (slope = 0.9514 and R2 = 0.9684). Certain interferents changed platelet recovery: RBC fragments and anti-platelet antibodies with the ISLH method; platelet fragments and anti-platelet antibodies on the rHEALTH; and RBC fragments, platelets fragments, triglycerides and LDL on the clinical impedance analyzer. The rHEALTH’s precision ranged from 3.1–8.0%, and the ISLH from 1.0–10.5%. Conclusions The rHEALTH method provides similar results with the reference method and good correlation between adult capillary and venous blood samples. This demonstrates the ability of the rHEALTH to provide point-of-care assessment of normal and thrombocytopenic platelet counts from fingerprick blood with high precision and limited interferences.


Sexual Health ◽  
2019 ◽  
Vol 16 (6) ◽  
pp. 598 ◽  
Author(s):  
Daniel Richardson ◽  
Colin Fitzpatrick ◽  
Fionnuala Finnerty ◽  
Debbie Williams

Men who have sex with men (MSM) with symptomatic secondary syphilis present with characteristic symptoms of rash, fever and lymphadenopathy; due to delays in microbiology results and some patients failing to return for treatment, empirical treatment is sometimes offered. We reviewed all patients presenting with secondary syphilis diagnosed on the basis of clinical symptoms and signs and reviewed treatment. Of the 36 patients, 16 MSM (44%; 95% confidence interval (CI) 27.8–60.2%) were treated empirically, whereas treatment was delayed for 20 (56%; 95% CI 39.8–72.2%) waiting for microbiology results. Treatment delays were longer for HIV-negative than HIV-positive MSM (10 vs 5 days respectively; P = 0.01); the cumulative treatment delay was 143 days. Concerns over antimicrobial resistance and overuse of antimicrobials should drive the use of point-of-care testing for syphlis.


2020 ◽  
Vol 58 (3) ◽  
pp. 445-455
Author(s):  
Annette Baumstark ◽  
Nina Jendrike ◽  
Ulrike Kamecke ◽  
Christina Liebing ◽  
Stefan Pleus ◽  
...  

AbstractBackgroundThe professional-use systems HemoCue® Glucose 201+ (HC201+) and HemoCue® Glucose 201 RT (HC201RT) are widely used for point-of-care testing (POCT) of blood glucose (BG). HC201RT utilizes unit-use microcuvettes which can be stored at room temperature, whereas HC201+ microcuvettes have to be stored at <8 °C. In this study, system accuracy of HC201+ and HC201RT was evaluated using capillary and venous blood samples.MethodsFor each system, two reagent system lots were evaluated within a period of 2 years based on testing procedures of ISO 15197:2013, a standard applicable for self-monitoring of blood glucose (SMBG) systems. For each reagent system lot, the investigation was performed by using 100 capillary and 95 to 99 venous blood samples. Comparison measurements were performed with a hexokinase laboratory method. Accuracy criteria of ISO 15197:2013 and POCT12-A3 were applied. In addition, bias was analyzed according to Bland and Altman, and error grid analysis was performed.ResultsWhen measuring capillary samples, both systems fulfilled accuracy requirements of ISO 15197:2013 and POCT12-A3 with the investigated reagent system lots. When measuring venous samples, only HC201+ fulfilled these requirements. Bias between HC201+ and reference measurements was more consistent over venous and capillary samples and microcuvette lots than for HC201RT. Error grid analysis showed that clinical actions might have been different depending on which system was used.ConclusionsIn this study, HC201+ showed a high level of accuracy irrespective of the sample type (capillary or venous). In contrast, HC201RT measurement results were markedly affected by the type of sample.


2019 ◽  
Vol 14 (5) ◽  
pp. 890-895 ◽  
Author(s):  
William D. Arnold ◽  
Kenneth Kupfer ◽  
Monica Hvidsten Swensen ◽  
Kyle S. Fortner ◽  
Harold E. Bays ◽  
...  

Background: Point-of-care (POC) HbA1c tests hold the promise of reducing the rates of undiagnosed diabetes, provided they exhibit acceptable analytical performance. The precision and total error of the POC (Afinion™ HbA1c Dx) test were investigated using whole blood samples obtained by fingerstick and venipuncture. Methods: Fingerstick samples spanning the assay range were collected from 61 subjects at three representative POC sites. At each site, six fingerstick samples were obtained from each subject and tested on the POC test across two (Afinion AS100) instruments. Repeatability, between-operator, and between-instrument components of variance were calculated using analysis of variance (ANOVA). Four venous samples (low, threshold, medium, and high HbA1c) were measured in duplicate across three instruments using three reagent lots, twice per day over 20-days. Repeatability, between-run, between-day, between-lot, and between-instrument components of variance were calculated. These fingerstick and venous blood results, combined with estimates of imprecision and bias from a prior investigation, allowed for the calculation of the total coefficient of variation (CV) and total error of the POC test using fingerstick and venous whole blood samples. Results: The total imprecision ranged from 1.30% to 2.03% CV using fingerstick samples and from 1.31% to 1.64% CV using venous samples. The total error ranged from 2.87% to 4.75% using fingerstick samples and from 2.93% to 3.80% using venous samples. Conclusions: The POC test evaluated here is precise across its measuring range using both fingerstick and venous whole blood. The calculated total error of the test is well under the accepted quality requirement of ≤6%.


2020 ◽  
Vol 120 (04) ◽  
pp. 687-691
Author(s):  
Majed A. Refaai ◽  
Vinay Shah ◽  
Ronald Fernando

Abstract Introduction There are limited publications about the microINR point-of-care (POC) system (iLine Microsystems). The current microINR POC system was compared with the ACL TOP 500 laboratory analyzer (Instrumentation Laboratory) and with the CoaguChek XS POC system (Roche Diagnostics). Methods This study was performed at three United States medical centers. Sixty-eight nonanticoagulated normal donors and 245 warfarin anticoagulated patients were included. Testing was performed in duplicate using capillary blood samples for the POC systems and venous blood samples for the laboratory testing. Accuracy and imprecision were assessed. Results Comparing microINR to ACL revealed a correlation coefficient (r) of 0.973, a slope of 1.00 (95% confidence interval [CI], 0.97–1.03), and an intercept of 0.08 (95% CI, 0.04–0.15). When compared with the CoaguChek XS, r was 0.977 with a slope of 0.92 (95% CI, 0.89–0.94) and an intercept of 0.15 (95% CI, 0.08–0.19). Predicted bias values at international normalized ratio (INR) 2.0, 3.5, and 4.5 were ≤ 5% against both references. Agreement with ACL was 97, 95, and 100% for the INR ranges of < 2.0 ± 0.40, 2.0 to 4.5 ± 20%, and ≥ 4.5 ± 25%, respectively. Agreement for the combined INR ranges was 96% against ACL and > 96% against the CoaguChek XS. The coefficient of variation of the microINR was 5.03% for INR < 2.0 and 4.68% for the therapeutic INR range 2.0 to 3.5. Conclusion The microINR results demonstrate adequate imprecision and accuracy to both ACL and CoaguChek XS. This indicates that monitoring INR by this microINR POC system is reliable and acceptable for the management of warfarin therapy.


2013 ◽  
Vol 2 (6) ◽  
pp. 259-265
Author(s):  
Amoo I T ◽  
Yakubu S E ◽  
Ado S A

The prevalence of malaria infection was determined in 400 patients (331 HIV positive and 69 HIV negative patients) in Kaduna metropolis and Zaria. The study combined the use of structured questionnaires and analysis of blood samples taken from consenting patients. The blood samples were analyzed using thick and thin blood films for malaria infection and enzyme linked immuno‐ sorbent assay for HIV analysis. Malaria infection was detected in 153 samples among HIV patients giving a prevalence of 46.2% and 36 samples among HIV negative patients giving a prevalence of 52.2%. HIV patients on highly active anti‐retroviral therapy (HAART) had a prevalence of 43.0% while HIV patients not on HAART had a prevalence of 55.1%. HIV negative patients had a prevalence of 52.2%. The prevalence recorded among HIV patients was high even though it was lower than that of HIV negative patients. This indicates that more attention and care needs to be given to HIV patients to reduce risks of malaria infection and also to significantly reduce the burden of malaria in endemic regions especially Sub‐Saharan Africa.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 688-688
Author(s):  
Patrick T. McGann ◽  
Erika Tyburski ◽  
Vysolela de Oliveira ◽  
Brigida Santos ◽  
Russell E. Ware ◽  
...  

Abstract Background: Severe anemia is a leading cause of morbidity and mortality among children in low-resource countries, particulalrly in sub-Saharan Africa, where malaria is endemic and sickle cell disease is prevalent. In many low-resource regions, particularly more remote areas, laboratory diagnostics are not always readily available. The utility of available equipment can be limited by lack of technical expertise, maintenance, and trained personnel, as well as lack of affordable reagents and reliable power. In a setting where severe, life-threatening anemia is common, it is critical for providers to have access to a rapid and accurate diagnostic tool to determine which patients need acute evaluation and treatment. A simple, rapid, accurate, and disposable point-of-care assay (AnemoCheck¨) has recently been tested and published(Tyburski et al. JCI 2014, in press), Hemoglobin concentration is measured by assessing the color of a chemical solution containing hydrogen peroxide and 3,3',5,5'-tetramethylbenzidine, after mixing with 10μL blood. The AnemoCheck assay is self-contained and does not require electricity, complicated sensors, or additional equipment. The color scale of the original assay correlated well with mild anemia (Hb 9-13 g/dL) but was not designed to discriminate lower hemoglobin concentrations. Accordingly, the test was modified to allow the color scale to detect more severe anemia (Hb 2.5-9.1 g/dL), but needs to be tested in a real-world setting where severe anemia is prevalent. Methods: The primary objective of this study was to determine whether AnemoCheck tests could measure hemoglobin concentrations at least as accurately as currently used standard laboratory techniques in low resource settings where severe anemia is common. The study was performed in the sickle cell clinic at Hospital Pedi‡trico David Bernardino, a large, public pediatric hospital in Luanda, Angola. After receiving informed consent from a parent or guardian, capillary blood was collected by fingerstick as per routine to measure hemoglobin using a BioSystems BTS-350 Hemoglobin Analyzer. A small sample of capillary blood was also collected for the AnemoCheck assay using a 10μL end-to-end capillary tube via capillary action (Sanguis Counting, Germany). Venous blood was also collected to measure hemoglobin using a calibrated hematology analyzer (Sysmex XT-2000i), which was considered the true hemoglobin concentration for comparison purposes. Hemoglobin was determined first by AnemoCheck by placing the 10μL capillary into a 2mL screw cap polypropylene tube containing the chemical reagents. The tube was then vigorously shaken and after 60 seconds, was compared to a standardized color scale and the hemoglobin concentration was determined. The AnemoCheck results were obtained and recorded before any additional machine-determined results were available, to avoid potential bias. Results: For this pilot study, samples were collected from 40 children for hemoglobin determination by all three methods. The range of hemoglobin concentrations, based on results from the Sysmex hematology analyzer, was 4.8 – 9.2 g/dL (median 7.0). As illustrated in the Figure, the hemoglobin values obtained from the AnemoCheck assay correlated well with the Sysmex hematology analyzer results, r=0.74, p<0.0001. The AnemoCheck results were more accurate than the hemoglobin values obtained by the BioSystems Hemoglobin Analyzer (r=0.47, p=0.020), which is the primary mode of hemoglobin determination in the clinic. On average, the hemoglobin obtained by AnemoCheck was within 0.5 g/dL of the Sysmex value (range 0-1.9 g/dL), compared to the Biosystems value (absolute mean difference=0.7 g/dL, range 0-2.2 g/dL). Figure 1 Figure 1. Conclusions: Laboratory diagnosis of anemia is expensive and difficult in low resource settings such as Angola, where severe anemia is common and life-threatening. Our pilot data demonstrate that a novel, point-of-care, color-based assay that does not require electricity or expensive reagents is able to accurately estimate low hemoglobin concentrations. Further refinements of the AnemoCheck assay will include photographic color assessment and automated hemoglobin estimation, which will be helpful in resource-poor settings. This test has the potential to become extremely useful diagnostic tool in low resource hospitals and health centers, where sophisticated equipment and reagents may not be available. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document